| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Pharmacology Section, Department of Medical Oncology, City of Hope National Medical Center, Duarte, California 91010, and Department of Medicine, University of Southern California School of Medicine, Los Angeles, California 90033
2 Recipient of a special fellowship from the Leukemia Society of America. To whom requests for reprints should be addressed, at the Pharmacology Section, Department of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, Calif. 91010.
This investigation examined the effect of the anthracycline antitumor agents on reactive oxygen metabolism in rat heart. Oxygen radical production by doxorubicin, daunorubicin, and various anthracycline analogues was determined in heart homogenate, sarcoplasmic reticulum, mitochondria, and cytosol, the major sites of cardiac damage by the anthracycline drugs. Superoxide production in heart sarcosomes was significantly increased by anthracycline treatment; for doxorubicin, the reaction appeared to follow saturation kinetics with an apparent Km of 112.62 µM, required NADPH as cofactor, was accompanied by the accumulation of hydrogen peroxide, and probably resulted from the transfer of electrons to molecular oxygen by the doxorubicin semiquinone after reduction of the drug by sarcosomal NADPH:cytochrome P-450 reductase (NADPH:ferricytochrome oxidoreductase, EC 1.6.2.4). Superoxide formation was also significantly enhanced by the anthracycline antibiotics in the mitochondrial fraction. Doxorubicin stimulated mitochondrial superoxide formation in a dose-dependent manner that also appeared to follow saturation kinetics (apparent Km of 454.55 µM); however, drug-related superoxide production by mitochondria required NADH rather than NADPH and was significantly increased in the presence of rotenone, which suggested that the proximal portion of the mitochondrial NADH dehydrogenase complex [NADH:(acceptor) oxidoreductase, EC 1.6.99.3] was responsible for the reduction of doxorubicin at this site. In heart cytosol, anthracycline-induced superoxide formation and oxygen consumption required NADH and were significantly reduced by allopurinol, a potent inhibitor of xanthine oxidase (xanthine:oxygen oxidoreductase, EC 1.2.3.2). Reactive oxygen production was detected in all of our studies despite the presence of both superoxide dismutase (superoxide:superoxide oxidoreductase, EC 1.15.1.1) and glutathione peroxidase (glutathione:hydrogen peroxide oxidoreductase, EC 1.11.1.9) in each cardiac fraction.
These results suggest that free radical formation by the anthracycline antitumor agents, which occurs in the same myocardial compartments that are subject to drug-induced tissue injury, may damage the heart by exceeding the oxygen radical detoxifying capacity of cardiac mitochondria and sarcoplasmic reticulum.
1 This study was supported by USPHS Grant 31788-02 from the National Cancer Institute, Department of Health and Human Services. Presented in part on May 28, 1980, at the Annual Meeting of the American Association for Cancer Research, Inc., in San Diego, Calif. (13).
Received 3/11/82. Accepted 10/28/82.
This article has been cited by other articles:
|
|
 |
|
  O. S. Bains, R. H. Takahashi, T. A. Pfeifer, T. A. Grigliatti, R. E. Reid, and K. W. Riggs Two Allelic Variants of Aldo-Keto Reductase 1A1 Exhibit Reduced in Vitro Metabolism of Daunorubicin Drug Metab. Dispos., May 1, 2008; 36(5): 904 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. St. Clair Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues Mol. Interv., June 1, 2007; 7(3): 147 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kobayashi-Miura, K. Shioji, Y. Hoshino, H. Masutani, H. Nakamura, and J. Yodoi Oxygen sensing and redox signaling: the role of thioredoxin in embryonic development and cardiac diseases Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2040 - H2050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yi, R. Bekeredjian, N. J. DeFilippis, Z. Siddiquee, E. Fernandez, and R. V. Shohet Transcriptional analysis of doxorubicin-induced cardiotoxicity Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1098 - H1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Doroshow Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J Natl Cancer Inst, February 15, 2006; 98(4): 223 - 225. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Conklin Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity Integr Cancer Ther, June 1, 2005; 4(2): 110 - 130. [Abstract] [PDF]
|
|
|
|
 |
|
 J. McHowat, L. M. Swift, K. N. Crown, and N. A. Sarvazyan Changes in Phospholipid Content and Myocardial Calcium-Independent Phospholipase A2 Activity during Chronic Anthracycline Administration J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 736 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chaiswing, M. P. Cole, D. K. St. Clair, W. Ittarat, L. I. Szweda, and T. D. Oberley Oxidative Damage Precedes Nitrative Damage in Adriamycin-Induced Cardiac Mitochondrial Injury Toxicol Pathol, August 1, 2004; 32(5): 536 - 547. [Abstract] [PDF]
|
|
|
|
 |
|
 S. FOGLI, P. NIERI, and M. C. BRESCHI The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage FASEB J, April 1, 2004; 18(6): 664 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, C. C. Chua, J. Gao, Z. Chen, C. L. C. Landy, R. Hamdy, and B. H. L. Chua Pifithrin-{alpha} protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H933 - H939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Lim, C. Zuppinger, X. Guo, G. M. Kuster, M. Helmes, H. M. Eppenberger, T. M. Suter, R. Liao, and D. B. Sawyer Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes J. Biol. Chem., February 27, 2004; 279(9): 8290 - 8299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hu, A. Krishan, W. Nie, K. S. Sridhar, L. D. Mayer, and M. Bally Synergistic Cytotoxicity of Pyrazoloacridine with Doxorubicin, Etoposide, and Topotecan in Drug-Resistant Tumor Cells Clin. Cancer Res., February 1, 2004; 10(3): 1160 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. To, M. Shin, M. Tabuchi, H. Sakaguchi, A. Takeuchi, N. Matsunaga, S. Higuchi, and S. Ohdo Influence of Dosing Schedule on Toxicity and Antitumor Effects of a Combination of Adriamycin and Docetaxel in Mice Clin. Cancer Res., January 15, 2004; 10(2): 762 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yamanaka, T. Tatsumi, J. Shiraishi, A. Mano, N. Keira, S. Matoba, J. Asayama, S. Fushiki, H. Fliss, and M. Nakagawa Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes J. Am. Coll. Cardiol., March 5, 2003; 41(5): 870 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shioji, C. Kishimoto, H. Nakamura, H. Masutani, Z. Yuan, S.-i. Oka, and J. Yodoi Overexpression of Thioredoxin-1 in Transgenic Mice Attenuates Adriamycin-Induced Cardiotoxicity Circulation, September 10, 2002; 106(11): 1403 - 1409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Childs, S. L. Phaneuf, A. J. Dirks, T. Phillips, and C. Leeuwenburgh Doxorubicin Treatment in Vivo Causes Cytochrome c Release and Cardiomyocyte Apoptosis, As Well As Increased Mitochondrial Efficiency, Superoxide Dismutase Activity, and Bcl-2:Bax Ratio Cancer Res., August 15, 2002; 62(16): 4592 - 4598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shizukuda and P. M. Buttrick Oxygen free radicals and heart failure: new insight into an old question Am J Physiol Lung Cell Mol Physiol, August 1, 2002; 283(2): L237 - L238. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mak and G. E. Newton The Oxidative Stress Hypothesis of Congestive Heart Failure : Radical Thoughts Chest, December 1, 2001; 120(6): 2035 - 2046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rabelo, K. De Angelis, P. Bock, T. Gatelli Fernandes, F. Cervo, A. Bello Klein, N. Clausell, and M. Claudia Irigoyen Baroreflex Sensitivity and Oxidative Stress in Adriamycin-Induced Heart Failure Hypertension, September 1, 2001; 38(3): 576 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Breitbart, L Lomnitski, A Nyska, Z Malik, M Bergman, Y Sofer, J K Haseman, and S Grossman Effects of water-soluble antioxidant from spinach, NAO, on doxorubicin-induced heart injury Human and Experimental Toxicology, July 1, 2001; 20(7): 337 - 345. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Batist, G. Ramakrishnan, C. S. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, P. Shah, A. Khojasteh, M. K. Nair, K. Hoelzer, et al. Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer J. Clin. Oncol., March 1, 2001; 19(5): 1444 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zhou, A. Starkov, M. K. Froberg, R. L. Leino, and K. B. Wallace Cumulative and Irreversible Cardiac Mitochondrial Dysfunction Induced by Doxorubicin Cancer Res., January 1, 2001; 61(2): 771 - 777. [Abstract] [Full Text]
|
|
|
|
|
|
T. Li and P. K. Singal Adriamycin-Induced Early Changes in Myocardial Antioxidant Enzymes and Their Modulation by Probucol Circulation, October 24, 2000; 102(17): 2105 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Forrest, B. Gonzalez, W. Tseng, X. Li, and J. Mann Human Carbonyl Reductase Overexpression in the Heart Advances the Development of Doxorubicin-induced Cardiotoxicity in Transgenic Mice Cancer Res., September 1, 2000; 60(18): 5158 - 5164. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Ide, H. Tsutsui, S. Kinugawa, H. Utsumi, D. Kang, N. Hattori, K. Uchida, K.-i. Arimura, K. Egashira, and A. Takeshita Mitochondrial Electron Transport Complex I Is a Potential Source of Oxygen Free Radicals in the Failing Myocardium Circ. Res., August 20, 1999; 85(4): 357 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Garner, M. J. I. Paine, I. Rodriguez-Crespo, E. C. Chinje, P. O. De Montellano, I. J. Stratford, D. G. Tew, and C. R. Wolf Nitric Oxide Synthases Catalyze the Activation of Redox Cycling and Bioreductive Anticancer Agents Cancer Res., April 1, 1999; 59(8): 1929 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K Singal, N. Khaper, V. Palace, and D. Kumar The role of oxidative stress in the genesis of heart disease Cardiovasc Res, December 1, 1998; 40(3): 426 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ichihara, Y. Yamada, and M. Yokota Association of a G994->T Missense Mutation in the Plasma Platelet-Activating Factor Acetylhydrolase Gene With Genetic Susceptibility to Nonfamilial Dilated Cardiomyopathy in Japanese Circulation, November 3, 1998; 98(18): 1881 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Venditti, M Balestrieri, T De Leo, and S Di Meo Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres Cardiovasc Res, June 1, 1998; 38(3): 695 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Siveski-Iliskovic, M. Hill, D.A. Chow, and P.K. Singal Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect Circulation, January 1, 1995; 91(1): 10 - 15. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. E. Davis Long-Term Complications of Antineoplastic Agents Journal of Pharmacy Practice, January 1, 1991; 4(2): 131 - 150. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
